Section Arrow
INBX.NASDAQ
- Inhibrx Biosciences Inc.
Quotes are at least 15-min delayed:2025/07/17 16:46 EDT
After Hours
Last
 23.62
0 (0.00%)
Bid
10
Ask
23.76
High 23.62 
Low 23.62 
Volume 392 
Regular Hours
Last
 23.62
-0.03 (-0.13%)
Day High 
24 
Prev. Close
23.65 
1-M High
24.295 
Volume 
103.80K 
Bid
10
Ask
23.76
Day Low
22.87 
Open
23.78 
1-M Low
13.97 
Market Cap 
342.36M 
Currency USD 
P/E 0.2 
%Yield -- 
10-SMA 20.36 
20-SMA 17.54 
50-SMA 14.78 
52-W High 24.295 
52-W Low 10.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
119.02/-2.14
Enterprise Value
348.81M
Balance Sheet
Book Value Per Share
6.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
200.00K
Operating Revenue Per Share
0.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.1.05+0.15+16.67%0.84PE
After Hours 1.09 +0.04 +3.81%
ABPAbpro Holdings Inc0.1962-0.022-10.08%-- 
After Hours 0.1963 +0.0001 +0.05%
NCNANuCana plc0.0468-0.0034-6.77%-- 
After Hours 0.0468 0 0.00%
ATNF180 Life Sciences Corp1.83+0.9497+107.88%0.11PE
After Hours 1.73 -0.1 -5.46%
MRKRMarker Therapeutics1.92+0.32+20.00%-- 
After Hours 1.92 0 0.00%
Quotes are at least 15-min delayed:2025/07/17 16:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.